MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jad.2020.02.003

Медицинская библиотека · Journal of affective disorders · 2020

Dose-effect of maternal serotonin reuptake inhibitor use during pregnancy on birth outcomes: A prospective cohort study.

Molenaar Nina M, Houtman Diewertje, Bijma Hilmar H, Brouwer Marlies E, Burger Huibert, Hoogendijk Witte J G, Bockting Claudi L H, Kamperman Astrid M, Lambregtse-van den Berg Mijke P

СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

While antidepressant use during pregnancy is increasingly common, there is concern about the possible effects of in-utero antidepressant exposure on the child. Our objective was to examine whether there is a dose-effect of maternal serotonin reuptake inhibitors (SRI) during pregnancy on birth outcomes.

METHODS

Women between 12 and 16 weeks of gestation, who were using an SRI, were eligible for participation in this nation-wide prospective observational cohort study. Recruitment took place between April 2015 and February 2018 (n = 145). SRI exposure and psychopathology symptoms were assessed throughout pregnancy. Exposure was defined as SRI standardized dose at 36 weeks of gestation and mean SRI standardized dose over total pregnancy. Multivariable linear and logistic regression were used to examine the associations with birth weight, gestational age at birth, and being small for gestational age.

RESULTS

Maternal SRI dose at 36 weeks of gestation was significantly associated with birth weight (adjusted ß = -180.7, 95%CI -301.1;-60.2, p-value < 0.01) as was mean SRI standardized dose during total pregnancy (adjusted ß = -187.3, 95%CI -322.0;-52.6, p-value < 0.01). No significant associations between maternal SRI dose and gestational age or being small for gestational age were observed.

LIMITATIONS: Although prospective, we cannot make full causal inferences given that we did not randomize women to different dosages.

CONCLUSION

These findings suggest that careful dosing of SRI use during pregnancy may prevent a negative impact on birth weight and indicate the need for further investigation of causality.

Для цитирования: Molenaar Nina M, Houtman Diewertje, Bijma Hilmar H, Brouwer Marlies E, Burger Huibert, Hoogendijk Witte J G, Bockting Claudi L H, Kamperman Astrid M, Lambregtse-van den Berg Mijke P. Dose-effect of maternal serotonin reuptake inhibitor use during pregnancy on birth outcomes: A prospective cohort study.. Journal of affective disorders. 2020. DOI: 10.1016/j.jad.2020.02.003.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.